Biocon Biologics Garners $75m ADQ Investment

Biocon Subsidiary Now Valued At More Than $4bn After Private Equity Deal

Biocon has secured the latest in a series of investments in its Biocon Biologics subsidiary, from Abu Dhabi based ADQ. The transaction, worth around $75m, values the biosimilars unit at $4.17bn.

Money Dollars Injection Investment
Biocon Biologics has received a further injection of capital • Source: Shutterstock

Biocon has secured a further investment in its Biocon Biologics subsidiary from Abu Dhabi based private equity group ADQ, “one of the region’s largest holding companies.”

More from Deals

More from Business